irritable bowel syndrome
Conditions
Interventions
Patients will, in this cross-over study, receive a maximum 6 chewing gums per
day, either containing cannabidiol, or a placebo chewing gum. Both
intervention periods will be 3 weeks with one week wa
Cannabidiol
Intestine
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: * Male * Female, only when using the contraceptive pill * Adults, aged 18-65 * IBS, diagnosed according to the Rome III criteria * More than 3 moments of pain a week with a VAS-score of 4 and higher * Signed informed consent
Exclusion criteria
Exclusion criteria: * Use of SSRIs, tramadol or tramagetic * History of intestinal surgery that might interfere with the outcome of the study * Female patients: currently pregnant, breast-feeding or intending to become pregnant during the study, judged by the persons self * Female who is not using the contraceptive pill. * Are an employee of the department of Human Nutrition at Wageningen UR, or employee of Ziekenhuis Gelderse Vallei * Participate in another research study * Alcohol use (male more than 14 servings a week, female more than 7 servings a week) * Hypersensitivity to one of the ingredients of the chewing gum * Cannabis use is from 3 months before untill the end of the study not allowed * Drug use (CYP2C19 and CYP3A4) metabolised; medication will be evaluated for this by the principal and medical investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigate the effect of administration of CBD by means of CanChew® chewing gum versus a placebo on pain, IBS symptoms and perceived wellbeing in patients with IBS. | — |
Secondary
| Measure | Time frame |
|---|---|
| n.a. | — |
Countries
The Netherlands
Outcome results
None listed